The company has voluntarily stopped enrolling new patients in the studies in response to reports of mostly mild or moderate ...

Bristol Myers Squibb has axed the degrader-antibody conjugate (DAC) it bought from Orum Therapeutics for $100 million, ...

A new biotech has sprung out of stealth with a bold vision to develop the “greatest therapeutic of all time”—a drug that can ...

New-look Novo is digging deeper into its metabolic roots with three new obesity programs purchased from New York biotech Kallyope. | New-look Novo is digging deeper into its metabolic roots with three ...

The FDA cleared Medtronic’s LigSure RAS Maryland jaw vessel sealer-divider to be used in combination with the device maker’s Hugo robotic-assisted surgery system. The device is geared toward providing ...

The FDA granted Aptitude its first 510(k) clearance for the next-generation Metrix COVID diagnostic that features three-times greater sensitivity with 30% faster results that its original emergency ...

Prediction markets are opening up new ways to bet on biopharma events, from clinical trial readouts to FDA approvals. | In this episode of “The Top Line,” we explore the growing space of biopharma ...

After decades of hard-won progress, ALS drug development is entering a new era, building on established efficacy measures like survival and ALSFRS-R with biology-driven science that captures the full ...

Electra Therapeutics is the latest biotech to overshoot its own IPO expectations this year, with the inflammation-focused company bringing in $350 million from this morning’s Nasdaq listing. | Electra ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

North Immunology has decided its path to taking its atopic dermatitis (AD) drug into the clinic involves going public via a ...

Novo’s race to rejuvenate its cardiometabolic portfolio has seen the rebranded Danish pharma pen a $1.4 biobucks pact with ...